We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serum Siderocalin Measured in Patients with TB and HIV

By LabMedica International staff writers
Posted on 14 Aug 2019
Print article
Image: The GeneXpert MTB/RIF assay is designed as a rapid diagnosis test of Tuberculosis (TB) and drug resistance (Photo courtesy of Cepheid).
Image: The GeneXpert MTB/RIF assay is designed as a rapid diagnosis test of Tuberculosis (TB) and drug resistance (Photo courtesy of Cepheid).
Tuberculosis (TB) continues to be a significant cause of morbidity and mortality worldwide. The progression from uninfected or latently infected to active TB is often insidious and has minimal symptoms in the initial months, resulting in delayed diagnosis and poor outcomes.

Mycobacterium tuberculosis produces high-affinity siderophores that play essential roles in iron acquisition and tuberculosis (TB) pathogenesis. In response, host cells secrete a siderophore-binding protein, siderocalin, to limit the bacteria’s access to iron. Human immunodeficiency virus (HIV) infection is well known to be associated with enhanced susceptibility to TB, but it is not clear whether alterations in siderocalin levels contribute to this susceptibility.

A team of scientists working with the Christian Medical College (Vellore, India) quantified serum siderocalin levels were quantified in four sets of individuals: HIV-infected patients with TB (HIVpos, TBpos), non-HIV-infected patients with TB (HIVneg, TBpos), HIV-infected patients without TB (HIVpos, TBneg), and healthy controls (HIVneg, TBneg). Serum samples from recruited patients were stored at −70°C and were used at the end of the study period for estimations.

TB was diagnosed by mycobacterial culture or Xpert MTB/RIF assay. Siderocalin was assayed using the neutrophil gelatinase-associated lipocalin (NGAL) enzyme-linked immunosorbent assay (ELISA) kit. The lower and upper limits of detection were 10 pg/mL and 1,000 pg/mL, respectively. Values outside these limits were recorded as being out of range.

The team reported that in the absence of TB, the median siderocalin concentration in healthy HIV-negative controls and HIV-positive individuals was 453 pg/mL and 268 pg/mL, respectively. TB infection considerably increased the siderocalin concentrations in each group. Specifically, HIVneg, TBpos patients had a median siderocalin concentration of 920 pg/mL, which was significantly higher compared to the HIVneg, TBneg controls. Similarly, HIVpos, TBpos patients had a median siderocalin concentration of 494 pg/mL, much higher than the HIVpos, TBneg controls. In addition, the difference between the mean siderocalin concentrations of HIVneg, TBpos (920 pg/mL) and HIVpos, TBpos (494 pg/mL) patients were found to be statistically significant. The median CD4 count in the HIVpos, TBneg controls were 302 (26–451) cells/μL, and among HIVpos, TBpos subjects was 93 (13–445) cells/μL. The difference in neutrophil counts between the HIVneg, TBneg and HIVneg, TBpos groups was also found to be statistically significant.

The authors concluded that their results indicate that active TB leads to an up-regulation of serum siderocalin regardless of HIV status, whereas HIV infection leads to a down-regulation of serum siderocalin levels in both TBneg and TBpos individuals. Further studies are needed to evaluate siderocalin as a potential marker of active TB and to clarify its role in the pathogenesis of HIV-associated TB. The study was published in the August 2019 issue of the International Journal of Infectious Diseases.

Related Links:
Christian Medical College

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.